SOLICITATION NOTICE
R -- Array CGH-EmArray Cyto6000 testing
- Notice Date
- 6/12/2009
- Notice Type
- Presolicitation
- NAICS
- 541380
— Testing Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse, Station Support/Simplified Acquisitions, 31 Center Drive, Room 1B59, Bethesda, Maryland, 20892
- ZIP Code
- 20892
- Solicitation Number
- 1110574
- Archive Date
- 7/12/2009
- Point of Contact
- Kathleen A Gregory, Phone: 301-435-2238
- E-Mail Address
-
gregoryk@nida.nih.gov
(gregoryk@nida.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- This is a notice of intent, not a request for a proposal. A solicitation document will not be issued and proposals will not be requested. National Institute on Drug Abuse, Office of Acquisitions- Neurosciences, Station Support/Simplified Acquisition, on behalf of the National Institute of Mental Health intends to negotiate and award a modification on a noncompetitive basis for continuation of services under current purchase order HHSN271200800620P. The services are increased in order to complete the NIMH protocol project under NCT00298246/06M0102. Emory Genetics Laboratory (EGL) will perform Array CGH – EmArray Cyto6000 testing and analysis for patients treated with autism. The test will include the hybridization of DNA analyses is isolated from peripheral blood to a custom array containing oligonucleotide clones across the genome for detection of any abnormal findings. The period of performance is also extended by 60 days. The protocol study shall provide the interrelationship between behavioral and medical profiles in children with autism. The study shall conduct a longitudinal natural history study of an addititional 50 children with autism. There are two types of study regressive and non-regressive groups from 12-84 months of age at study entry in order to capture regression. The systematic prospective evaluations will be utilized in order to provide validation to the phenomenon of regression in autism, determine diagnostic and functional outcomes, and evaluate behavioral, medical and immunologic functioning. Specific aims include. 1. To characterize and validate the regressive phenotype in children with autism. 2. To characterize the immune response in children with autism. 3. To identify neurobiologic markers for autism through the techniques of neurophysiology, anatomy, metabolomics, proteomics and genomics (e.g. gene expression profiles). The acquisition is being conducted under simplified acquisition using FAR 13 procedures and is exempt from the requirements of FAR Part 6, Competition Requirement. This notice of intent is not a request for competitive proposals. Interested parties may identify their interest and capabilities in response to this synopsis. The determination by the Government not to compete the proposed contract based upon responses to this notice is solely with the discretion of the Government. Emory University is the only known laboratory to provide such clinical array testing for the NIMH protocols. Comments to this announcement, referencing synopsis number NOI1110574 may be submitted to the NIDA, Station Support/Simplified Acquisition Branch, 31 Center Drive, Bldg 31, Room 1B59, Bethesda, MD 20892-2080, and Attention: Kathleen Gregory, Contracting Officer.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NIDA-2/1110574/listing.html)
- Place of Performance
- Address: Bethesda, Maryland, 20892, United States
- Zip Code: 20892
- Zip Code: 20892
- Record
- SN01844033-W 20090614/090613000246-3b025f5cbc633b1984e7ce1594b2818d (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |